AGN tested the two highest-tolerated doses from the phase-1
It could be insufficient differentiation from Lucentis on efficacy or duration of time the effect was sustained for, which will translate to injections frequency. Either way, if there was a dose response, they can try an even higher dose to improved one or both parameters. Needless to say I'm not as optimistic as before.
Market Data 
Markets 
AI
